(ANSA) – CHICAGO, June 06 – The new therapy against Her2-low type metastatic breast cancer with so-called ‘conjugated antibodies’ can be defined as an unprecedented and “revolutionary intelligent chemotherapy”. This was explained in a press conference at the Congress of the American Society of Clinical Oncology (ASCO) by Giusepe Curigliano, Professor of Medical Oncology at the University of Milan and Director of the Development of New Drugs and Innovative Therapies at the European Institute of Oncology ( Ieo).
It is, underlined the expert commenting on the study on the conjugated antibody trastuzumab-deruxtecan presented at the ASCO congress, of a “new therapy that will revolutionize the treatment for thousands of patients” with advanced breast cancer: “they can in fact benefit from it – has underlined – tens of thousands of breast cancer patients with low expression of the Her2 protein (Her2-low), but also patients with triple negative breast cancer, particularly difficult to treat, always with low level of the Her2 protein “. Now, Curigliano’s invitation, “it will be very important to disseminate this information to ensure that the many patients who have an indication can access the therapy, for now in the context of the present trials since the drug it has not yet received the approval of the regulatory agencies. “
The conjugated antibody, explains the expert, “represents a new therapeutic frontier and acts as a sort of Trojan horse: the antibody is in fact linked, ‘conjugated’ to the chemotherapy drug and, once in the body, it takes it directly into the tumor cell. Hence the definition of intelligent chemotherapy, since the chemotherapy is administered in a targeted way into the tumor cell “. (HANDLE).
breaking latest news © Copyright ANSA
<![CDATA[]]>
var userAccept = $.cookie(‘cb-enabled’);
var cookieAccepted = (userAccept != null && userAccept.indexOf(‘accepted’) != -1);
if (cookieAccepted) {
(function($n,e,o,d,a,t,a$) {
$n._4wRecom = $n._4wRecom || {};
$n._4wRecom.Q = $n._4wRecom.Q || [];
$n._4wRecom.Q.push([‘setup’, function () {
$n._4wRecom.T.setTaxonomy(“/ansa/ansa/ansa.it/ambiente”);
$n._4wRecom.B.addPosition(“ansa_ansa_ambiente”,”NeoWidget”);
}]);
var x = d.createElement(e), s = d.getElementsByTagName(e)[0];
x.src = (‘https:’ == t.protocol ? ‘https://js-ssl’ : ‘http://js’)+o;
x.async = a;
s.parentNode.insertBefore(x, s);
}) (window,’scr’+’ipt’,’.neodatagroup.com/4wr.js’,document,1,location,1);
}
<![CDATA[]]>
<![CDATA[]]>